With the growing body of research into psychedelic medicines such as psilocybin and methylenedioxymethamphetamine (MDMA), pharmacists are sure to become crucial in the management and handling of these novel treatments. One important role for pharmacists in this space will be managing adverse effects (AEs) and potential drug-drug interactions. In an interview with Pharmacy Times, expert Kelan Thomas, PharmD, MS, discussed what pharmacists should know about this rapidly changing space.